Difference between revisions of "Team:NCTU Formosa"

 
(37 intermediate revisions by 6 users not shown)
Line 4: Line 4:
 
<link href="https://2015.igem.org/Team:NCTU_Formosa/wiki_reset?action=raw&ctype=text/css" rel="stylesheet">
 
<link href="https://2015.igem.org/Team:NCTU_Formosa/wiki_reset?action=raw&ctype=text/css" rel="stylesheet">
 
<script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>
 
<script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>
 +
<script>
 +
$(document).ready(function(){
 +
 
 +
    if($(".div3").innerHeight()<$(".div3-1").innerHeight()){
 +
        $(".div3").css("height",$(".div3-3").innerHeight());
 +
       
 +
    };
  
 +
});
 +
</script>
 
<style>
 
<style>
 
         body{
 
         body{
Line 19: Line 28:
 
         .div2{
 
         .div2{
 
         background:#fff;
 
         background:#fff;
−
height:90vh;
+
height:100vh;
 
         width:100%;
 
         width:100%;
 
         position:relative;
 
         position:relative;
Line 27: Line 36:
 
         background:#fff;
 
         background:#fff;
 
         width:100%;
 
         width:100%;
−
height:80vh;
+
height:100vh;
 
         position:relative;
 
         position:relative;
 
          
 
          
Line 34: Line 43:
 
         background:#fff;
 
         background:#fff;
 
         width:28%;
 
         width:28%;
 +
height:18vw;
 
         position:absolute;
 
         position:absolute;
−
         left:8%;
+
         left:8%;
−
height:100%;
+
 
top:0vh;
 
top:0vh;
 
         margin-left:0;  
 
         margin-left:0;  
Line 43: Line 52:
 
         background:#fff;
 
         background:#fff;
 
         width:28%;
 
         width:28%;
−
height:100%;
+
height:18vw;
 +
 
position:absolute;
 
position:absolute;
 
         left:36%;
 
         left:36%;
Line 52: Line 62:
 
         background:#fff;
 
         background:#fff;
 
         width:28%;
 
         width:28%;
−
height:100%;
+
height:18vw;
 +
 
position:absolute;
 
position:absolute;
 
         left:64%;
 
         left:64%;
Line 71: Line 82:
 
         video#bgvid{  
 
         video#bgvid{  
 
position:relative;
 
position:relative;
−
top:100px;
+
top:80px;
 
         min-width: 72%;
 
         min-width: 72%;
 
         min-height: 72%;
 
         min-height: 72%;
Line 105: Line 116:
 
font-size: 18px;
 
font-size: 18px;
 
text-decoration:none;
 
text-decoration:none;
−
text-align:left;
+
text-align: justify;
−
position:absolute;
+
margin-left : 8%;
−
top:50%;
+
−
left:8%;
+
−
height:50%;
+
 
width:80%;
 
width:80%;
 
}
 
}
Line 129: Line 137:
 
font-size: 18px;
 
font-size: 18px;
 
text-decoration:none;
 
text-decoration:none;
−
text-align:left;
+
text-align: justify;
 
position:absolute;
 
position:absolute;
 
top:50%;
 
top:50%;
Line 141: Line 149:
 
width:100%;
 
width:100%;
 
position:relative;
 
position:relative;
−
background-size:70%;
+
background-size:50%;
 
background-repeat:no-repeat;
 
background-repeat:no-repeat;
 
left:5%;
 
left:5%;
Line 152: Line 160:
 
font-size: 18px;
 
font-size: 18px;
 
text-decoration:none;
 
text-decoration:none;
−
text-align:left;
+
text-align: justify;
 
position:absolute;
 
position:absolute;
 
top:50%;
 
top:50%;
Line 168: Line 176:
 
background-repeat: no-repeat;  
 
background-repeat: no-repeat;  
 
}
 
}
−
 
+
.div3 img{
 +
width:85%;
 +
margin-left:7.5%;
 +
}
 
</style>
 
</style>
 
   </head>
 
   </head>
Line 177: Line 188:
 
<div class="div1">
 
<div class="div1">
 
<div class="div1-1">
 
<div class="div1-1">
−
<video autoplay id="bgvid" control="false">
+
<video autoplay id="bgvid" controls="true">
−
<source src="https://static.igem.org/mediawiki/2015/4/4a/Nctu_formosa_homepage_video2.mp4" type="video/mp4">
+
<source src="https://static.igem.org/mediawiki/2015/0/09/Nctu_formosa_homepage_vide5.mp4" type="video/mp4">
 
</source>
 
</source>
 
         </video>
 
         </video>
Line 186: Line 197:
 
     <div class="div2">
 
     <div class="div2">
 
<div class="p-2"></div>
 
<div class="p-2"></div>
−
         <div style="position:absolute;bottom:20%;width:100%;text-align:center;font-size:18pt;letter-spacing:5px;">The only thing we can detect is everything.</div>
+
         <div style="position:absolute;bottom:30%;width:100%;text-align:center;font-size:18pt;letter-spacing:5px;">The only thing we can detect is everything.</div>
 
</div>
 
</div>
 
      
 
      
 
     <div class="div3 ">
 
     <div class="div3 ">
 
<div class="div3-1">
 
<div class="div3-1">
−
  <div class="photo3-1"></div>
+
−
         
+
          <img src="https://static.igem.org/mediawiki/2015/5/51/2015_NCTU_Formosa_Homepage_21.png" align="center" height=250px>  
−
      <div class="photocontent1"><h2>Who are we</h2>
+
      <div class="photocontent1"><h2>Who we are</h2>
−
        NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO  
+
      NCTU_Formosa created an organization—APOllO, which stands for Almighty Probe of scFv Organization. APOllO is devoted to developing detection technology by utilizing antibodies. In 2015, we cooperated with iGEM to create a brand new detection platform using synthetic biology.</div>
−
        devoted to developing detection technology by utilizing antibodies. In 2015, We cooperated with iGEM with Synthetic 
+
−
        Biology to develop a brand new detection platform. </div>
+
 
    </div>
 
    </div>
 
              
 
              
 
         <div class="div3-2">
 
         <div class="div3-2">
−
  <div class="photo3-2"></div>
+
    <img src="https://static.igem.org/mediawiki/2015/2/2e/NCTU_Formosa_Homepage_antibody.png" align="middle" height=250px>  
−
      <div class="photocontent2"><h2>What's new</h2>
+
      <div class="photocontent1"><h2>What's new</h2>
 
  APOllO E.Cotector:<br>   
 
  APOllO E.Cotector:<br>   
−
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen-antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.
+
Our organization creates a customized scFv detection platform by co-transforming any desired plasmid in to <i>E. coli</i>. ScFv utilizes antigen-antibody interaction to act as probes. Therefore, our E.Cotector has the function of a detector.
 
      </div> </div>
 
      </div> </div>
 
              
 
              
 
           <div class="div3-3">
 
           <div class="div3-3">
−
    <div class="photo3-3"></div>
+
    <img src="https://static.igem.org/mediawiki/2015/7/77/Nctu_formosa_homepage_photo3.jpg" align="middle" height=250px>  
 
             
 
             
−
        <div class="photocontent3"><h2>What do we care</h2>
+
        <div class="photocontent1"><h2>What we care about</h2>
 
         
 
         
−
In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more patients can afford it. Therefore, more patients can be prescribed and treated, lowering the mortality rate of cancer.<br>
+
In 2015, we focused on helping doctors select appropriate candidates for monoclonal-antibody targeted drug treatments—reducing the price of patients' treatment. If the cost for diagnosis decreases, more patients can afford it. Therefore lowering the mortality rate of cancer. <br>
 
             </div>
 
             </div>
 
      </div>
 
      </div>

Latest revision as of 02:41, 19 September 2015

The only thing we can detect is everything.

Who we are

NCTU_Formosa created an organization—APOllO, which stands for Almighty Probe of scFv Organization. APOllO is devoted to developing detection technology by utilizing antibodies. In 2015, we cooperated with iGEM to create a brand new detection platform using synthetic biology.

What's new

APOllO E.Cotector:
Our organization creates a customized scFv detection platform by co-transforming any desired plasmid in to E. coli. ScFv utilizes antigen-antibody interaction to act as probes. Therefore, our E.Cotector has the function of a detector.

What we care about

In 2015, we focused on helping doctors select appropriate candidates for monoclonal-antibody targeted drug treatments—reducing the price of patients' treatment. If the cost for diagnosis decreases, more patients can afford it. Therefore lowering the mortality rate of cancer.